$SLRX
Salarius Pharmaceuticals, Inc. Stock $slrx

$slrx Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-K Financial Statement

#000161521918000018 Filed on March 07, 2018

Income Statement

Concept	2018 Q1	2017 Q4	2017 Q3
Revenue	$178.6K	$282.8K	$413.6K
YoY Change	-26.37%	-5.38%	-30.96%
Cost Of Revenue	$83.93K	$133.3K	$148.8K
YoY Change	6.1%	-0.27%	-32.72%
Gross Profit	$94.65K	$149.5K	$264.8K
YoY Change	-42.09%	-9.51%	-29.93%
Gross Profit Margin	53.0%	52.85%	64.03%
Selling, General & Admin	$3.700M	$3.980M	$4.930M
YoY Change	-19.39%	1.53%	-9.54%
% of Gross Profit	3909.22%	2662.47%	1861.47%
Research & Development	$4.680M	$4.259M	$4.739M
YoY Change	19.55%	0.67%	-16.34%
% of Gross Profit	4944.83%	2849.35%	1789.48%
Depreciation & Amortization	$64.07K	$70.00K	$80.00K
YoY Change	-29.88%	-36.36%	0.0%
% of Gross Profit	67.69%	46.83%	30.21%
Operating Expenses	$8.461M	$8.376M	$9.823M
YoY Change	-1.48%	1.12%	-13.33%
Operating Profit	-$8.283M	-$8.093M	-$9.409M
YoY Change	-0.76%	1.36%	-12.35%
Interest Expense	$60.00K	$60.00K	$80.00K
YoY Change	-25.0%	-25.0%	-20.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$8.220M	-$8.030M	-$9.330M
YoY Change	-0.6%	0.57%	-13.09%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$381.5K	-$8.029M	-$9.332M
YoY Change	-95.39%	1.63%	-12.27%
Net Earnings / Revenue	-213.65%	-2838.66%	-2256.31%
Basic Earnings Per Share
Diluted Earnings Per Share	-$11.42M	-$11.31M	-$13.33M
COMMON SHARES
Basic Shares Outstanding	17.97M shares	17.97M shares	17.97M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q1	2017 Q4	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$23.90M	$33.30M	$38.90M
YoY Change	-54.73%	-45.5%	-42.2%
Cash & Equivalents	$22.07M	$19.19M	$20.41M
Short-Term Investments	$2.000M	$14.10M	$18.80M
Other Short-Term Assets	$1.300M	$800.0K	$1.100M
YoY Change	-18.75%	-11.11%	-31.25%
Inventory	$418.2K	$431.9K	$534.0K
Prepaid Expenses
Receivables	$12.63K	$10.39K	$35.13K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$25.64M	$34.54M	$40.55M
YoY Change	-53.24%	-44.71%	-41.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$266.6K	$331.0K	$401.0K
YoY Change	-44.36%	-40.49%	-35.26%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$100.0K	$0.00	$0.00
YoY Change	54.32%	-100.0%	-100.0%
Total Long-Term Assets	$393.2K	$457.6K	$654.2K
YoY Change	-41.37%	-38.8%	-19.31%
TOTAL ASSETS
Total Short-Term Assets	$25.64M	$34.54M	$40.55M
Total Long-Term Assets	$393.2K	$457.6K	$654.2K
Total Assets	$26.03M	$34.99M	$41.21M
YoY Change	-53.1%	-44.64%	-41.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.241M	$2.004M	$919.0K
YoY Change	173.74%	68.13%	-26.88%
Accrued Expenses	$1.800M	$3.700M	$3.900M
YoY Change	-21.74%	42.31%	56.0%
Deferred Revenue		$72.19K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.121M	$5.848M	$4.973M
YoY Change	28.03%	50.36%	27.08%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00	$100.0K
YoY Change	-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$100.0K
YoY Change	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.121M	$5.848M	$4.973M
Total Long-Term Liabilities	$0.00	$0.00	$100.0K
Total Liabilities	$4.145M	$5.887M	$5.027M
YoY Change	26.47%	51.04%	28.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$119.3M	-$111.1M	-$103.1M
YoY Change	40.45%	44.93%	49.9%
Common Stock	$1.798K	$1.780K	$1.754K
YoY Change	5.58%	6.08%	6.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.316M	-$2.900M	$36.18M
YoY Change
Total Liabilities & Shareholders Equity	$26.03M	$34.99M	$41.21M
YoY Change	-53.1%	-44.64%	-41.09%

Cashflow Statement

Concept	2018 Q1	2017 Q4	2017 Q3
OPERATING ACTIVITIES
Net Income	-$381.5K	-$8.029M	-$9.332M
YoY Change	-95.39%	1.63%	-12.27%
Depreciation, Depletion And Amortization	$64.07K	$70.00K	$80.00K
YoY Change	-29.88%	-36.36%	0.0%
Cash From Operating Activities	-$9.412M	-$5.750M	-$8.050M
YoY Change	14.43%	-8.73%	11.03%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$10.00K	-$50.00K
YoY Change	-100.0%	-80.0%	-77.27%
Acquisitions
YoY Change
Other Investing Activities	$12.12M	$4.670M	-$10.75M
YoY Change	75.65%	396.81%	193.72%
Cash From Investing Activities	$12.12M	$4.660M	-$10.79M
YoY Change	76.13%	423.6%	178.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$54.91K	0.000	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-$9.412M	-5.750M	-8.050M
Cash From Investing Activities	$12.12M	4.660M	-10.79M
Cash From Financing Activities	$54.91K	0.000	0.000
Net Change In Cash	$2.762M	-1.090M	-18.84M
YoY Change	-305.48%	-79.85%	69.42%
FREE CASH FLOW
Cash From Operating Activities	-$9.412M	-$5.750M	-$8.050M
Capital Expenditures	$0.00	-$10.00K	-$50.00K
Free Cash Flow	-$9.412M	-$5.740M	-$8.000M
YoY Change	14.12%	-8.16%	13.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017	dei	Amendment Flag AmendmentFlag	false
CY2017	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2017	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017	dei	Document Period End Date DocumentPeriodEndDate	2017-12-31
CY2017	dei	Document Type DocumentType	10-K
CY2017	dei	Entity Central Index Key EntityCentralIndexKey	0001615219
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17972166	shares
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2017Q2	dei	Entity Public Float EntityPublicFloat	39700000	USD
CY2017	dei	Entity Registrant Name EntityRegistrantName	Flex Pharma, Inc.
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2016Q4	flks	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	2587573	USD
CY2017Q4	flks	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	3712221	USD
CY2016Q4	flks	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	938665	USD
CY2017Q4	flks	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	2502400	USD
CY2017Q4	flks	Cash Cash Equivalentsand Marketable Securities CashCashEquivalentsandMarketableSecurities	33315759	USD
CY2017	flks	Common Stock Numberof Votes CommonStockNumberofVotes	1	vote
CY2016Q4	flks	Deferred Tax Liabilities Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxLiabilitiesTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	23316	USD
CY2017Q4	flks	Deferred Tax Liabilities Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxLiabilitiesTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4490	USD
CY2017	flks	Effective Income Tax Rate Reconciliation Tax Credit Payroll Tax Credit Election Amount EffectiveIncomeTaxRateReconciliationTaxCreditPayrollTaxCreditElectionAmount	22000	USD
CY2015	flks	Effective Income Tax Rate Reconciliation Tax Credit Payroll Tax Credit Election Percent EffectiveIncomeTaxRateReconciliationTaxCreditPayrollTaxCreditElectionPercent	0.000
CY2016	flks	Effective Income Tax Rate Reconciliation Tax Credit Payroll Tax Credit Election Percent EffectiveIncomeTaxRateReconciliationTaxCreditPayrollTaxCreditElectionPercent	0.000
CY2017	flks	Effective Income Tax Rate Reconciliation Tax Credit Payroll Tax Credit Election Percent EffectiveIncomeTaxRateReconciliationTaxCreditPayrollTaxCreditElectionPercent	-0.007
CY2015	flks	Initial Public Offering Costs Paid InitialPublicOfferingCostsPaid	575245	USD
CY2016	flks	Initial Public Offering Costs Paid InitialPublicOfferingCostsPaid	0	USD
CY2017	flks	Initial Public Offering Costs Paid InitialPublicOfferingCostsPaid	0	USD
CY2015	flks	Proceedsfrom Early Exerciseof Stock Options ProceedsfromEarlyExerciseofStockOptions	400000	USD
CY2016	flks	Proceedsfrom Early Exerciseof Stock Options ProceedsfromEarlyExerciseofStockOptions	0	USD
CY2017	flks	Proceedsfrom Early Exerciseof Stock Options ProceedsfromEarlyExerciseofStockOptions	0	USD
CY2015	flks	Property And Equipment Purchases In Accounts Payableand Accrued Expense PropertyAndEquipmentPurchasesInAccountsPayableandAccruedExpense	106680	USD
CY2016	flks	Property And Equipment Purchases In Accounts Payableand Accrued Expense PropertyAndEquipmentPurchasesInAccountsPayableandAccruedExpense	7100	USD
CY2017	flks	Property And Equipment Purchases In Accounts Payableand Accrued Expense PropertyAndEquipmentPurchasesInAccountsPayableandAccruedExpense	0	USD
CY2014Q1	flks	Related Party Transaction Percentage Of Gross Sales Due To Related Parties RelatedPartyTransactionPercentageOfGrossSalesDueToRelatedParties	0.02
CY2014	flks	Related Party Transaction Percentage Of Gross Sales Due To Related Parties RelatedPartyTransactionPercentageOfGrossSalesDueToRelatedParties	0.02
	flks	Revenue Recognition Refund Period RevenueRecognitionRefundPeriod	P30D
	flks	Revenue Recognition Refund Period RevenueRecognitionRefundPeriod	P21D
CY2016Q4	flks	Share Based Compensation Award Shares Reserved For Future Issuance ShareBasedCompensationAwardSharesReservedForFutureIssuance	2722573	shares
CY2017Q4	flks	Share Based Compensation Award Shares Reserved For Future Issuance ShareBasedCompensationAwardSharesReservedForFutureIssuance	3439820	shares
CY2016Q4	flks	Shares Reserved For Future Issuance SharesReservedForFutureIssuance	4273934	shares
CY2017Q4	flks	Shares Reserved For Future Issuance SharesReservedForFutureIssuance	4149082	shares
CY2017	flks	Tax Cutsand Jobs Act Changein Tax Rate Deferred Tax Asset Income Tax Expense TaxCutsandJobsActChangeinTaxRateDeferredTaxAssetIncomeTaxExpense	12600000	USD
CY2017	flks	Tax Cutsand Jobs Actof2017 Incomplete Accounting Provisional Income Tax Expense Benefit TaxCutsandJobsActof2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit	0	USD
CY2015Q1	flks	Underwriting Discountsand Commissions Initial Public Offering UnderwritingDiscountsandCommissionsInitialPublicOffering	6150134	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1192183	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2004440	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12181	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10385	USD
CY2016Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	42024	USD
CY2017Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	107595	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	153219	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	227980	USD
CY2015Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	0	USD
CY2016Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	4000	USD
CY2017Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	3000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	323014	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	622883	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1614	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1247	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	135962935	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	140184630	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6597359	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6572963	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4219165	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	7998871	USD
CY2015	us-gaap	Advertising Expense AdvertisingExpense	0	USD
CY2016	us-gaap	Advertising Expense AdvertisingExpense	2936000	USD
CY2017	us-gaap	Advertising Expense AdvertisingExpense	3566000	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6597359	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6572963	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4219165	USD
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4027235	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3353042	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2755479	shares
CY2016Q4	us-gaap	Assets Assets	63214979	USD
CY2017Q4	us-gaap	Assets Assets	34992772	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	62467269	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	34535137	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	38658933	USD
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	14129723	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2912	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	38	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4526	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1285	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	38660547	USD
CY2017Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	14130970	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	16519620	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	8191315	USD
CY2016	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	0	USD
CY2017	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	0	USD
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	19888	USD
CY2016Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	6	security
CY2017Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	6	security
CY2014Q4	us-gaap	Cash Cash	33854153	USD
CY2015Q4	us-gaap	Cash Cash	66686695	USD
CY2016Q4	us-gaap	Cash Cash	22416040	USD
CY2017Q4	us-gaap	Cash Cash	19186036	USD
CY2015	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	32832542	USD
CY2016	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-44270655	USD
CY2017	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-3230004	USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17970590	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17972166	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16773798	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17797178	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	1678	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	1780	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29166284	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39470083	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-34433295	USD
CY2015Q1	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	6971108	shares
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	197020	USD
CY2016Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	110931	USD
CY2016Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	221090	USD
CY2016Q4	us-gaap	Cost Of Goods Sold CostOfGoodsSold	133706	USD
CY2016	us-gaap	Cost Of Goods Sold CostOfGoodsSold	662747	USD
CY2017Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	79106	USD
CY2017Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	145325	USD
CY2017Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	148756	USD
CY2017Q4	us-gaap	Cost Of Goods Sold CostOfGoodsSold	133343	USD
CY2017	us-gaap	Cost Of Goods Sold CostOfGoodsSold	506530	USD
CY2016Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	26927	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4490	USD
CY2015Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	1848737	USD
CY2016Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	21095	USD
CY2017Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	58821	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8398	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	39214	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	88344	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	72188	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	28154538	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	28538245	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	26927	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4490	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	24322172	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	24744841	USD
CY2016Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	32171	USD
CY2017Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	35783	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1423292	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1964189	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1847441	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1591131	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	529462	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	202301	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	28127611	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	28533755	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	0	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	0	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	3611	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0	USD
CY2015	us-gaap	Depreciation Depreciation	49881	USD
CY2016	us-gaap	Depreciation Depreciation	277231	USD
CY2017	us-gaap	Depreciation Depreciation	324548	USD
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.08
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.61
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.71
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.65
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.48
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.43
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.49
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.51
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
CY2017Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.46
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.99
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.341
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.392
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.011
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.365
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.002
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.007
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.026
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.063
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.019
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.004
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.001
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.013
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.034
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.050
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.050
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.018
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.019
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.022
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1453665	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	874246	USD
CY2017	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M4D
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	4533000	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16464279	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5111695	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5377784	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5447847	USD
CY2016Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3918661	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4990943	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19855987	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4594716	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4934937	USD
CY2017Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3983088	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18503684	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	621393	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	309437	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	819357	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	12181	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1796	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1570216	USD
CY2016	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	746879	USD
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1124648	USD
CY2015	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-18881	USD
CY2016	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-9475	USD
CY2017	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	68542	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	88344	USD
CY2017	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-16156	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	454132	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-22241	USD
CY2015	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-100103	USD
CY2016	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	64800	USD
CY2017	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-64800	USD
CY2015	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
CY2016	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-15442	USD
CY2017	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	538178	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	17409	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-148881	USD
CY2015	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	27	USD
CY2016	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-240	USD
CY2017	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	0	USD
CY2015	us-gaap	Interest Income Operating InterestIncomeOperating	72028	USD
CY2016Q1	us-gaap	Interest Income Operating InterestIncomeOperating	103333	USD
CY2016Q2	us-gaap	Interest Income Operating InterestIncomeOperating	107818	USD
CY2016Q3	us-gaap	Interest Income Operating InterestIncomeOperating	97726	USD
CY2016Q4	us-gaap	Interest Income Operating InterestIncomeOperating	84232	USD
CY2016	us-gaap	Interest Income Operating InterestIncomeOperating	393109	USD
CY2017Q1	us-gaap	Interest Income Operating InterestIncomeOperating	77854	USD
CY2017Q2	us-gaap	Interest Income Operating InterestIncomeOperating	72342	USD
CY2017Q3	us-gaap	Interest Income Operating InterestIncomeOperating	77339	USD
CY2017Q4	us-gaap	Interest Income Operating InterestIncomeOperating	64429	USD
CY2017	us-gaap	Interest Income Operating InterestIncomeOperating	291964	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	454132	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	431891	USD
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	17411	USD
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	434244	USD
CY2017Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	414480	USD
CY2016	us-gaap	Inventory Write Down InventoryWriteDown	282000	USD
CY2017	us-gaap	Inventory Write Down InventoryWriteDown	42000	USD
CY2015	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-9523	USD
CY2016	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-16161	USD
CY2017	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	68139	USD
CY2016Q4	us-gaap	Liabilities Liabilities	3897593	USD
CY2017Q4	us-gaap	Liabilities Liabilities	5886884	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	63214979	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34992772	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3889195	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5847670	USD
CY2016Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	38658933	USD
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	14129723	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	80843751	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	22098	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2632	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27265091	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12240880	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	24489562	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20746118	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32051873	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27722198	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-29141630	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-9592461	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-11363133	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-10637494	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-7900035	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-39493123	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-8268395	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-8804623	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-9332113	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-8028531	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-34433662	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29141630	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-39493123	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-34433662	USD
CY2017	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2017	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2015	us-gaap	Operating Expenses OperatingExpenses	29213658	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	9695794	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	11583636	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	11334294	USD
CY2016Q4	us-gaap	Operating Expenses OperatingExpenses	8283171	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	40896895	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	8588796	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	9212488	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	9823053	USD
CY2017Q4	us-gaap	Operating Expenses OperatingExpenses	8375788	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	36000125	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-29213658	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9695794	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-11470951	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10735220	USD
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-7984267	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-39886232	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8346249	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8876965	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9409452	USD
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-8092960	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-34725626	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	777655	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	466593	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	311062	USD
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	253000	USD
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	337000	USD
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	522000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	64800	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2015	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-24654	USD
CY2016	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	23040	USD
CY2017	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	367	USD
CY2015	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-24654	USD
CY2016	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	23040	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	367	USD
CY2015	us-gaap	Other Noncash Expense OtherNoncashExpense	4123	USD
CY2016	us-gaap	Other Noncash Expense OtherNoncashExpense	3434	USD
CY2017	us-gaap	Other Noncash Expense OtherNoncashExpense	1781	USD
CY2015	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
CY2016Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
CY2016Q2	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
CY2016Q3	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	12940	USD
CY2016Q4	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	7805	USD
CY2016	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	20745	USD
CY2017Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	2255	USD
CY2017Q2	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	4835	USD
CY2017Q3	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	6360	USD
CY2017Q4	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	76	USD
CY2017	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	13526	USD
CY2015Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	8000000	USD
CY2015	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	39397769	USD
CY2016	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	38682081	USD
CY2017	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	32987697	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	265617	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	559378	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	113498	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	925983	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	777102	USD
CY2015Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	79900000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	79900000	USD
CY2015	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	80435430	USD
CY2016	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2017	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2015	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	12398295	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	26995324	USD
CY2017	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	57585413	USD
CY2015	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2016	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	5255	USD
CY2017	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	5344	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8321	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	22098	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2632	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	879329	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	953923	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	556315	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	331040	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12749379	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4387079	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6094921	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5665357	USD
CY2016Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4230804	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20378161	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3914974	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4076220	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4739360	USD
CY2017Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4259357	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16989911	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	126595	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	126595	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-76645613	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-111079275	USD
CY2015	us-gaap	Royalty Expense RoyaltyExpense	0	USD
CY2016	us-gaap	Royalty Expense RoyaltyExpense	20000	USD
CY2017	us-gaap	Royalty Expense RoyaltyExpense	25000	USD
CY2015	us-gaap	Sales Discounts Goods SalesDiscountsGoods	0	USD
CY2016	us-gaap	Sales Discounts Goods SalesDiscountsGoods	135000	USD
CY2017	us-gaap	Sales Discounts Goods SalesDiscountsGoods	278000	USD
CY2015	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0	USD
CY2016Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	112685	USD
CY2016Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	586134	USD
CY2016Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	291099	USD
CY2016	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	989918	USD
CY2017Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	240292	USD
CY2017Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	330688	USD
CY2017Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	407241	USD
CY2017Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	282752	USD
CY2017	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1260973	USD
CY2015	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	112685	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	599074	USD
CY2016Q4	us-gaap	Sales Revenue Net SalesRevenueNet	298904	USD
CY2016	us-gaap	Sales Revenue Net SalesRevenueNet	1010663	USD
CY2017Q1	us-gaap	Sales Revenue Net SalesRevenueNet	242547	USD
CY2017Q2	us-gaap	Sales Revenue Net SalesRevenueNet	335523	USD
CY2017Q3	us-gaap	Sales Revenue Net SalesRevenueNet	413601	USD
CY2017Q4	us-gaap	Sales Revenue Net SalesRevenueNet	282828	USD
CY2017	us-gaap	Sales Revenue Net SalesRevenueNet	1274499	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	6597359	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	6572963	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	4219165	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1404844	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.21
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	149386	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	64302	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2606	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	215041	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	418642	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	994748	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	763320	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1059500	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.55
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.35
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.80
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1605684	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	803600	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2156250	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2580491	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.66
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.65
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	803600	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2580491	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	6.65
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	8.63
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.59
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.67
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	10.51
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.87
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.20
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	692232	USD
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y6M22D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y11M9D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M18D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y6M18D
CY2016Q4	us-gaap	Shares Held In Employee Stock Option Plan Committed To Be Released SharesHeldInEmployeeStockOptionPlanCommittedToBeReleased	354569	shares
CY2017Q4	us-gaap	Shares Held In Employee Stock Option Plan Committed To Be Released SharesHeldInEmployeeStockOptionPlanCommittedToBeReleased	534274	shares
CY2015	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	0	USD
CY2016	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	170000	USD
CY2017	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	261000	USD
CY2017	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	0	shares
CY2017	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	0	shares
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	47280	shares
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	8516	shares
CY2017	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1576	shares
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	79860185	USD
CY2015	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2016	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2017	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	408321	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	22098	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2632	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-6538340	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	92192408	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	59317386	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	29105888	USD
CY2015Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.2335
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	406000	USD
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14032916	shares
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15843532	shares
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16105555	shares
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16361617	shares
CY2016Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16619596	shares
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16233985	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16873512	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17130264	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17386249	shares
CY2017Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17642646	shares
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17260626	shares
CY2017	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of credit risk and off-balance sheet risk</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash, cash equivalents and marketable securities are financial instruments that potentially subject the Company to concentrations of credit risk. The Company's cash, cash equivalents and marketable securities are held in accounts at financial institutions that management believes are creditworthy. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of risk</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company outsources the manufacture of HOTSHOT to a single co-packer that produces bottled finished goods. The Company also sources certain raw materials from sole suppliers. A disruption in the supply of materials or the production of finished goods could significantly impact the Company's revenues in the future as alternative sources of raw materials and co-packing may not be available at commercially reasonable rates or within a reasonably short period of time. </font></div></div>
CY2017	us-gaap	Revenue Recognition Discounts RevenueRecognitionDiscounts	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Discounts provided to customers are accounted for as a reduction of product revenue, and were approximately </font><font style="font-family:Arial;font-size:10pt;">$278,000</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$135,000</font><font style="font-family:Arial;font-size:10pt;"> for the years ended </font><font style="font-family:Arial;font-size:10pt;">December 31, 2017</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December 31, 2016</font><font style="font-family:Arial;font-size:10pt;">, respectively. </font></div></div>
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company's management evaluates its estimates, which include, but are not limited to, estimates related to inventory write-offs, clinical study accruals, stock-based compensation expense, and amounts of expenses during the reported period. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prior to the Company's IPO, the Company utilized significant estimates and assumptions in determining the fair value of its common stock. The Company utilized various valuation methodologies in accordance with the framework of the 2004 and 2013 American Institute of Certified Public Accountants Technical Practice Aids, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</font><font style="font-family:Arial;font-size:10pt;">, to estimate the fair value of its common stock. Each valuation methodology included estimates and assumptions that required the Company's judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company's common stock at the time and the likelihood of achieving a liquidity event, such as an initial public offering or a sale of the Company. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of common stock at each valuation date and may have materially affected the financial statements.</font></div></div>

Files In Submission

Name	View Source	Status
0001615219-18-000018-index-headers.html	Edgar Link	pending
0001615219-18-000018-index.html	Edgar Link	pending
0001615219-18-000018.txt	Edgar Link	pending
0001615219-18-000018-xbrl.zip	Edgar Link	pending
figure1a04.jpg	Edgar Link	pending
figure2a07.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
flks-20171231.xml	Edgar Link	completed
flks-20171231.xsd	Edgar Link	pending
flks-20171231_cal.xml	Edgar Link	unprocessable
flks-20171231_def.xml	Edgar Link	unprocessable
flks-20171231_lab.xml	Edgar Link	unprocessable
flks-20171231_pre.xml	Edgar Link	unprocessable
flks2017123110-k.htm	Edgar Link	pending
flks20171231ex-231.htm	Edgar Link	pending
flks20171231ex-311.htm	Edgar Link	pending
flks20171231ex-312.htm	Edgar Link	pending
flks20171231ex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLRX
Salarius Pharmaceuticals, Inc. Stock $slrx

2018 Q1 Form 10-K Financial Statement

#000161521918000018 Filed on March 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLRX Salarius Pharmaceuticals, Inc. Stock $slrx

2018 Q1 Form 10-K Financial Statement

#000161521918000018 Filed on March 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLRX
Salarius Pharmaceuticals, Inc. Stock $slrx